Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vadhan-Raj

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
International Journal of Radiation Oncology, Biology, Physics|February 11, 1998
Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I studyB Glisson, R Komaki, J S Lee, et al.
Blood|October 1, 1989
Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndromeS Vadhan-Raj, H E Broxmeyer, G Spitzer, et al.
The New England Journal of Medicine|December 22, 1988
Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factorS Vadhan-Raj, S Buescher, H E Broxmeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sitesS Vadhan-Raj, C Cordon-Cardo, E Carswell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 1992
Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell levelS Vadhan-Raj, H E Broxmeyer, W N Hittelman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcomaS Vadhan-Raj, N E Papadopoulos, M A Burgess, et al.
Blood Cancer Journal|January 9, 2016
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trialN Raje, S Vadhan-Raj, W Willenbacher, et al.
Annals of Internal Medicine|February 26, 2000
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancerS Vadhan-Raj, C F Verschraegen, C Bueso-Ramos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 2, 2012
Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acidS Vadhan-Raj, R von Moos, L J Fallowfield, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2015
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristicsA Lipton, K Fizazi, A T Stopeck, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
International Journal of Radiation Oncology, Biology, Physics|February 11, 1998
Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I studyB Glisson, R Komaki, J S Lee, et al.
Blood|October 1, 1989
Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndromeS Vadhan-Raj, H E Broxmeyer, G Spitzer, et al.
The New England Journal of Medicine|December 22, 1988
Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factorS Vadhan-Raj, S Buescher, H E Broxmeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1988
Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sitesS Vadhan-Raj, C Cordon-Cardo, E Carswell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 1992
Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell levelS Vadhan-Raj, H E Broxmeyer, W N Hittelman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcomaS Vadhan-Raj, N E Papadopoulos, M A Burgess, et al.
Blood Cancer Journal|January 9, 2016
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trialN Raje, S Vadhan-Raj, W Willenbacher, et al.
Annals of Internal Medicine|February 26, 2000
Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancerS Vadhan-Raj, C F Verschraegen, C Bueso-Ramos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 2, 2012
Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acidS Vadhan-Raj, R von Moos, L J Fallowfield, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2015
Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristicsA Lipton, K Fizazi, A T Stopeck, et al.
Pageof 9